Eisai’s thyroid cancer drug Lenvima gets positive opinion from EMA’s CHMP
Lenvima is an orally administered molecular targeted agent which inhibits the activities of several different molecules such as VEGFR, FGFR, RET, KIT and PDGFR. Mainly, the agent simultaneously
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.